Allscripts Healthcare Solutions Inc

Find Ratings Reports
MDRX : NASDAQ : Technology
$11.97 | %
Today's Range: 11.94 - 12.18
Avg. Daily Volume: 1870700.0
04/28/17 - 4:00 PM ET

Financial Analysis


ALLSCRIPTS HEALTHCARE SOLTNS's gross profit margin for the fourth quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALLSCRIPTS HEALTHCARE SOLTNS has weak liquidity. Currently, the Quick Ratio is 0.75 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has decreased by 12.45% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)425.44345.65
EBITDA ($mil)68.4460.85
EBIT ($mil)16.5324.32
Net Income ($mil)2.8816.33


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)96.61116.87
Total Assets ($mil)3832.162681.95
Total Debt ($mil)1331.38625.57
Equity ($mil)1232.471407.88


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin53.4353.87
EBITDA Margin16.0817.6
Operating Margin3.887.04
Sales Turnover0.40.52
Return on Assets0.07-0.08
Return on Equity0.23-0.15
Debt Q4 FY16 Q4 FY15
Current Ratio0.911.05
Debt/Capital0.520.31
Interest Expense20.167.4
Interest Coverage0.823.29


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)180.51189.31
Div / share0.00.0
EPS-0.040.09
Book value / share6.837.44
Institutional Own % n/a n/a
Avg Daily Volume1861723.02518766.0

Valuation


HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 1.74 indicates a discount versus the S&P 500 average of 2.99 and a significant discount versus the industry average of 5.66. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, ALLSCRIPTS HEALTHCARE SOLTNS proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MDRX NM Peers 225.24   MDRX 7.98 Peers 26.16

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

MDRX's P/E is negative making this valuation measure meaningless.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MDRX is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MDRX 16.51 Peers 36.79   MDRX NA Peers 0.94

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

MDRX is trading at a significant discount to its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MDRX 1.74 Peers 5.66   MDRX -1300.00 Peers -49.25

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MDRX is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, MDRX is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MDRX 1.38 Peers 5.55   MDRX 11.79 Peers 20.67

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MDRX is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

MDRX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades